14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TYRA vs MLYS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Tyra Biosciences, Inc. (TYRA) is the stronger overall head-to-head candidate over Mineralys Therapeutics, Inc. (MLYS) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). TYRA carries a Unified Composite Score of 32.4/100 (SELL) at $20.18 (N/M Forward P/E, 0.0% operating margin), whereas MLYS carries 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MLYS currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. TYRA 32.4/100 SELL), TYRA captures the overall institutional head-to-head verdict (3–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile MLYS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TYRA vs MLYS. Trailing 12-month operating profitability (TYRA 0.0% vs MLYS 0.0%) and valuation multiples (TYRA N/M vs MLYS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TYRA vs MLYS Key Questions & Quantitative Answers
As of Nov 16, 2026, Tyra Biosciences, Inc. (TYRA) is the stronger overall head-to-head candidate over Mineralys Therapeutics, Inc. (MLYS) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). TYRA carries a Unified Composite Score of 32.4/100 (SELL) at $20.18 (N/M Forward P/E, 0.0% operating margin), whereas MLYS carries 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MLYS currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. TYRA 32.4/100 SELL), TYRA captures the overall institutional head-to-head verdict (3–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile MLYS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MLYS leads the Growth & Scale pillar: TYRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MLYS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TYRA generates N/A in USD-normalized revenue versus N/A for MLYS. In operating R&D and SG&A reinvestment, TYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLYS.
TYRA and MLYS trade at balanced relative valuation multiples. TYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MLYS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TYRA (-34.9% ROE) versus MLYS (-68.5% ROE) capital efficiency.
In options market volatility and institutional positioning, TYRA carries 69.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 12.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 49% Vol realized risk). By comparison, MLYS carries 89.9% implied volatility (39th %ile, Balanced (25th–60th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.